Tech Company Financing Transactions
TuHURA Biosciences Funding Round
On 6/3/2025, TuHURA Biosciences landed $12.5 million in funding from private investors.
Transaction Overview
Company Name
Announced On
6/3/2025
Transaction Type
Venture Equity
Amount
$12,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10500 University Center Drive 110
Tampa, FL 33612
USA
Tampa, FL 33612
USA
Phone
Website
Email Address
Overview
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Bianco
Chief Financial Officer
Dan Dearborn
Executive Vice President
Bertrand Le Bourdonnec
VP - Operations
Peter O'Neill
VP - Regulatory Affairs
Adeana Dorsey
VP - Regulatory Affairs
Michael Krsulich
Browse more venture capital transactions:
Prev: 6/3/2025: Clara Home Care venture capital transaction
Next: 6/3/2025: Ciroos venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs